Document is current
Any future updates will be listed below
-
Authors
Shin, Min-Hye
Lee, Young-Jae
Park, Kyung Eun
Kim, Yeonhee
Won, Ha-Kyeong
Ahn, Kyung-Min
Shim, Ji-Su
Kim, Min-Hye
An, Jin
Jeong, Jiung
Kim, Young-Chan
Lee, Hwa Young
Kang, Sung-Yoon
Park, Han-Ki
Jo, Eun-Jung
Lee, Seung-Eun
Kim, So Ri
Chang, Yoon-Seok
Lee, Byung-Jae
Morice, Alyn H.
Song, Woo-Jung
,
Birring, Surinder S
Cho, Sang-Heon
Kang, Noeul
Kim, Byung-Keun
Kim, Mi-Yeong
Kim, Sae-Hoon
Kim, Sang-Heon
Kim, Sang-Hoon
Kwon, Hyouk-Soo
Lee, Ji-Ho
Lee, Ji-Hyang
Moon, Ji-Yong
Morice, Alyn H
Oh, Ji-Yoon
Park, So-Young
Yoo, Youngsang
-
Funding
Funding for this research was provided by:
the Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp
- License Information
-
More Information
Article History
Received: 11 June 2025
Accepted: 10 July 2025
First Online: 20 July 2025
Declarations
:
: AHM has received consulting fees from Bayer, Bellus, GSK, Merck, NeRRe, Shionogi, and Trevi; lecture fees from Boehringer Ingelheim, Merck, and Chiesi; and grant support from Bayer, Bellus, GSK, Merck, Nocion, Philips, NeRRe, Shionogi, and Trevi. He is a founder and CEO of Tussogenics Ltd. WJS declares grants from Merck Sharp & Dohme Corp., Daewoong Pharmaceutical, and AstraZeneca, consulting fees from Merck, Bellus, AstraZeneca, Shionogi, and GSK, and lecture fees from Thermo Fischer/Immunotek, Celltrion, Merck, AstraZeneca, GSK, Sanofi, and Novartis. Other authors have none to declare.
